Share Name Share Symbol Market Type Share ISIN Share Description
Valirx LSE:VAL London Ordinary Share GB00BWWYSP41 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 2.375p 856,398 16:07:58
Bid Price Offer Price High Price Low Price Open Price
2.25p 2.50p 2.50p 2.375p 2.375p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -3.55 -1.90 10.8

Valirx (VAL) Latest News

More Valirx News
Valirx Takeover Rumours

Valirx (VAL) Share Charts

1 Year Valirx Chart

1 Year Valirx Chart

1 Month Valirx Chart

1 Month Valirx Chart

Intraday Valirx Chart

Intraday Valirx Chart

Valirx (VAL) Discussions and Chat

Valirx Forums and Chat

Date Time Title Posts
15/7/201817:08Valirx 2018 and Beyond2,348
15/7/201816:33Valirx 2018 for Rampers,Derampers and P&D have your say..1,559
12/7/201812:14K9p and VALIRX 201834
01/7/201802:37ValiRx Plc - exceptional cancer theraputic developments883
20/6/201818:08Hopeisforever and Valirx 52

Add a New Thread

Valirx (VAL) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Valirx trades in real-time

Valirx (VAL) Top Chat Posts

DateSubject
15/7/2018
09:20
Valirx Daily Update: Valirx is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker VAL. The last closing price for Valirx was 2.38p.
Valirx has a 4 week average price of 2p and a 12 week average price of 2p.
The 1 year high share price is 7.73p while the 1 year low share price is currently 0.93p.
There are currently 454,962,717 shares in issue and the average daily traded volume is 0 shares. The market capitalisation of Valirx is £10,805,364.53.
25/6/2018
08:07
sicilian_kan: I hope that shareholders are going to start waking up here. I appreciate that there has been significant dilution in recent times and that the talks have for a long time not come to fruition, however there are very strong indications in the past few weeks that the corner has been turned. Recently, VAL has confirmed: 1. By RNS, excellent 401 data 2. By RNS, stating that they are in "advanced conversations" 3. By Video Interview, confirming that there have been "legal negotiations" Whatever has happened in the past, it is quite clear that VAL is now at a stage where commerciality is, in the next 1-10 weeks, a real possibility. Companies do not state the word "advanced" without having good reason for stating it and the company's advisers would have had to ensure that the comment was accurate. Usually "legal negotiations" means that terms are being discussed. The conclusion may not be guaranteed - they may not agree terms or the terms could be contingent upon certain things happening. But this is a significantly more advanced step that being in discussions with someone and suggests a good chance of a deal being struck in the coming weeks / months. This turning of the corner was apparent to those such as me, with fresh eyes coming into VAL for the first time. I hope that the change in Align Research's position from activist to supportive of the company, also persuades even the most hardened cynic at VAL, that change is likely on its way. The risk, remains, as before, as further dilution. The downside is therefore say a 1/3rd hit on one's investment with funding at 2p. The potential upside I think is, conservatively, 1-5x bagging on a 401 licensing deal. All depends of course on the terms reached. The risk reward ratio is therefore very attractive to me and the evidence suggests that even IF dilution happens of say 7-8%, at some point in the next 1-10 weeks a deal will be done and the price rise should dwarf that. I of course hope that there is just the licensing deal. It is this risk reward ratio that makes the investment case here strong. Of course, there is risk and no promises can be made. But the very favourable risk reward ratio is what Align also confirm today as their concluding point: "That the company has potentially very valuable products with material market penetration opportunities has never been in question and post the meet we are more emboldened in our view of the unique asymmetric risk/reward opportunity presented at the current stock price. We look forward to hoped for progress on the commercialisation front unfolding in the months ahead." Here's hoping that the share price increases as the market gains greater confidence that VAL will commercialise at least one of its products in the not too distant future. Personally, I would still be buying these shares at 5p, though I will not need to as I have filled my boots at 2.75p. The best buying opportunities are when the share price and sentiment are low.
11/6/2018
16:46
thebossman: OPEN LETTER TO THE BOARD OF VALIRX June 10, 2018 | Posted by admin OPEN LETTER Dear Ms Vainikka I write this letter to you in an open format as Align Research is all about transparency and, collectively with other shareholders, as ultimate owners of the company, we believe that all shareholders should be given the courtesy of weighing up the points we raise here. Whilst not wishing to be overly aggressive, should you ignore this letter and the points detailed herein, I can now confirm that we have commitments for in excess of 5% of the shareholder register to bring an EGM for your and potentially other BoD members’ removal and will, if it is necessary, not hesitate in catalysing this. I bring to your attention the following concerns we have with regards to the current stewardship of the company: Since 2016 I count that there has been six outright equity placings (with warrant overhangs to the placing brokers) aswell as the Yorkville and Bracknor facilities totalling funding of £7.75m. The share count during this period has risen from just over 43m shares to an incredible 407m – a near ten fold increase. It is safe to say that those loyal shareholders over the past two years have been veritably decimated unless they had bottomless pockets. More disconcertingly, during this period I cannot see any director participation in these fund raisings but yet you felt it appropriate in February of this year to award to the management slate options over 10% of the company. I believe the words complete misalignment are appropriate here. It is quite laughable that the prior options had strikes ranging between 43.125p and 125p – a prime example of “heads we win, tails you lose” that shareholders have suffered. As if the above is not illustrative of the fact that you are (a) disconnected from shareholders and (b) actually appearing to act at cross purposes to their interests, you have collectively as a Board taken just shy of £1m during the last 2 years. This, whilst the stock price has fallen from near 60p to less than 1p at the low point. If ever the moniker “reward for failure” was applicable, that very point surely is it. The third most damning observation re non alignment with shareholders is that your collective holding of stock is de minimis. Indeed, I cannot see that you hold any shares from the last set of Report and Accounts nor have you as a BoD participated in any of the placings over the last 2 years aside from a nominal & derisory £10k purchase apiece last spring. This is utterly incredible and to me and spells one of three things – either (a) you are collectively “potless”; which is not a good position for any management personnel to be in let alone for their shareholders, (b) you do not believe in the company’s products and development stage or (c), such is the system in place allowing you to reprice share options that you do not believe it is actually necessary to “step upto the plate” and show your alignment with your long suffering shareholders. Each of these scenarios are clearly not good for the company’s owners. The Yorkville and Bracknor de facto death spiral financings have been, in large part, the primary decimants of the stock price. As a shareholder, and given the stage of development that Valirx is now at, I want reassurance that this type of financing is no longer to be used – it is the death knell for many a company and reflects to the wider market that normal equity financing of such volume is not available. Again, not good for shareholders. Towards the tail end of last year the stock actually did rise materially on the VAL201 Clinical trial results. Given that there was a decent chunk of warrants in issue (43m) with an exercise price of 5p expiring March 2019 why did you believe it necessary to cut shareholders legs from beneath them again with a placing at 4.25p when they were beginning to be exercised? The exercise of these would have brought in over £2m – in excess of the placing sum and have been less dilutive of course. I posit that this is again illustrative of the abject disregard for existing minority shareholders by you and the BoD and that it has continued to foster the belief that management cannot be trusted not to continually throw prior placee participants under a bus. You can see from above that there is a quite damning list of non shareholder friendly activities that have taken place on your watch and the share price collapse presents, we believe, an unarguable case. The course you have taken this last few years has only served to cut both the market cap and the credibility of the company. To be clear, the purpose of this letter is to bring the current course that has been so damaging to all shareholders to a halt and with as minimum disruption to the company as possible. I do actually believe that Valirx is now on the cusp of real commercial applications of its key products but my confidence in current shareholders benefiting from this is, for obvious reasons as relayed here, extremely low. With the above in mind I would like you to show collectively as a BoD a new commitment to your shareholders through the following actions: A rebasing of your and Dr George Morris’ salary to £60,000 p.a. From a performance bonus perspective you are more than adequately incentivised now re the generous share options you recently struck yourselves with an exercise price of just 4p and near 10 years of life. The appointment of a new NED to represent shareholders interests and replacing Kevin Alexander. I am happy to liaise on an appropriate party in this role. I note CFO Mr Dessler has a loan repayable from the company of £41,030. Subject to restricted period dealing clearance I would suggest that this be converted into stock at the current price in showing his faith in the way forward. Collective directors purchasing of stock on market (subject to non restricted period dealing issues) of a minimum of £100,000 in, again, showing your faith in the way forward. A clear funding pathway disclosure over the next 18 months with a commitment to not utilise death spiral financing and a dual commitment that any such funding requirements be offered to existing shareholders by way of an open offer. I sincerely hope that you take seriously the points raised here and that you communicate with all Valirx shareholders on these issues. I repeat again, ignorance of these matters will result in the calling of an EGM for wholesale BoD replacements. Yours faithfully R Jennings
11/6/2018
16:42
thebossman: Align research OPEN LETTER TO THE BOARD OF VALIRX June 10, 2018 | Posted by admin OPEN LETTER Dear Ms Vainikka I write this letter to you in an open format as Align Research is all about transparency and, collectively with other shareholders, as ultimate owners of the company, we believe that all shareholders should be given the courtesy of weighing up the points we raise here. Whilst not wishing to be overly aggressive, should you ignore this letter and the points detailed herein, I can now confirm that we have commitments for in excess of 5% of the shareholder register to bring an EGM for your and potentially other BoD members’ removal and will, if it is necessary, not hesitate in catalysing this. I bring to your attention the following concerns we have with regards to the current stewardship of the company: Since 2016 I count that there has been six outright equity placings (with warrant overhangs to the placing brokers) aswell as the Yorkville and Bracknor facilities totalling funding of £7.75m. The share count during this period has risen from just over 43m shares to an incredible 407m – a near ten fold increase. It is safe to say that those loyal shareholders over the past two years have been veritably decimated unless they had bottomless pockets. More disconcertingly, during this period I cannot see any director participation in these fund raisings but yet you felt it appropriate in February of this year to award to the management slate options over 10% of the company. I believe the words complete misalignment are appropriate here. It is quite laughable that the prior options had strikes ranging between 43.125p and 125p – a prime example of “heads we win, tails you lose” that shareholders have suffered. As if the above is not illustrative of the fact that you are (a) disconnected from shareholders and (b) actually appearing to act at cross purposes to their interests, you have collectively as a Board taken just shy of £1m during the last 2 years. This, whilst the stock price has fallen from near 60p to less than 1p at the low point. If ever the moniker “reward for failure” was applicable, that very point surely is it. The third most damning observation re non alignment with shareholders is that your collective holding of stock is de minimis. Indeed, I cannot see that you hold any shares from the last set of Report and Accounts nor have you as a BoD participated in any of the placings over the last 2 years aside from a nominal & derisory £10k purchase apiece last spring. This is utterly incredible and to me and spells one of three things – either (a) you are collectively “potless”; which is not a good position for any management personnel to be in let alone for their shareholders, (b) you do not believe in the company’s products and development stage or (c), such is the system in place allowing you to reprice share options that you do not believe it is actually necessary to “step upto the plate” and show your alignment with your long suffering shareholders. Each of these scenarios are clearly not good for the company’s owners. The Yorkville and Bracknor de facto death spiral financings have been, in large part, the primary decimants of the stock price. As a shareholder, and given the stage of development that Valirx is now at, I want reassurance that this type of financing is no longer to be used – it is the death knell for many a company and reflects to the wider market that normal equity financing of such volume is not available. Again, not good for shareholders. Towards the tail end of last year the stock actually did rise materially on the VAL201 Clinical trial results. Given that there was a decent chunk of warrants in issue (43m) with an exercise price of 5p expiring March 2019 why did you believe it necessary to cut shareholders legs from beneath them again with a placing at 4.25p when they were beginning to be exercised? The exercise of these would have brought in over £2m – in excess of the placing sum and have been less dilutive of course. I posit that this is again illustrative of the abject disregard for existing minority shareholders by you and the BoD and that it has continued to foster the belief that management cannot be trusted not to continually throw prior placee participants under a bus. You can see from above that there is a quite damning list of non shareholder friendly activities that have taken place on your watch and the share price collapse presents, we believe, an unarguable case. The course you have taken this last few years has only served to cut both the market cap and the credibility of the company. To be clear, the purpose of this letter is to bring the current course that has been so damaging to all shareholders to a halt and with as minimum disruption to the company as possible. I do actually believe that Valirx is now on the cusp of real commercial applications of its key products but my confidence in current shareholders benefiting from this is, for obvious reasons as relayed here, extremely low. With the above in mind I would like you to show collectively as a BoD a new commitment to your shareholders through the following actions: A rebasing of your and Dr George Morris’ salary to £60,000 p.a. From a performance bonus perspective you are more than adequately incentivised now re the generous share options you recently struck yourselves with an exercise price of just 4p and near 10 years of life. The appointment of a new NED to represent shareholders interests and replacing Kevin Alexander. I am happy to liaise on an appropriate party in this role. I note CFO Mr Dessler has a loan repayable from the company of £41,030. Subject to restricted period dealing clearance I would suggest that this be converted into stock at the current price in showing his faith in the way forward. Collective directors purchasing of stock on market (subject to non restricted period dealing issues) of a minimum of £100,000 in, again, showing your faith in the way forward. A clear funding pathway disclosure over the next 18 months with a commitment to not utilise death spiral financing and a dual commitment that any such funding requirements be offered to existing shareholders by way of an open offer. I sincerely hope that you take seriously the points raised here and that you communicate with all Valirx shareholders on these issues. I repeat again, ignorance of these matters will result in the calling of an EGM for wholesale BoD replacements. Yours faithfully R Jennings If the past is anything to go by then sod all will come out of this letter.. Maybe valirx will say we are doing our best..
04/5/2018
16:05
thebossman: Today 15:23 Price: 3.25 applegarth 12,172 posts OXB consolidation I quoted OXB last week as a comparison with VAL with OXB having 8x more shares than us at 3.2billion but with a share price 4x greater at 12.5p. Now they are consolidating 50 for1 new share bringing the share price to �6 p/s and 64m in issue. If my past experience with consolidations is any gauge to go by...the share price nearly always retraces again, considerably only to regain most of the losses if really good news comes out. OXB could drop to as low as �2 over the next few months if they keep dragging their feet...LT investors have waited for over 20yrs but have achieved a lot with Novartis. I have generally found that whilst good solid companies can make it work, those down in the lower reaches such as in AIM tend to use the small number of resultant shares as an excuse to dilute again at a later date. Let's face it they are only in the position of having huge numbers of shares through incessant dilution in the first place. I mention this only to compare the two VAL and OXB. We have had our consolidation and a few placings since. At some point the dilutions must stop and be replaced by a well funded JV or buyout. IF VAL thinks they can begin the same old old malarky all over again, i'm afraid they'll have to consider how investors will react. I for one won't stand any more delays beyond this year...it's too long. Fingers crossed for a life changing deal, gla Observation Strong Buy This poster is forgetting val did a 125-1 consolidation and at the time our share price was about 0.00225
25/4/2018
18:34
thebossman: 16.40 ValiRx PLC Second Price Monitoring Extn... Lol May 2015 was the last time we the about statement or similar.. . Lol ValiRx PLC Stmnt re Share Price Movement RNS Number : 3571O ValiRx PLC 27 May 2015 ValiRx Plc ('ValiRx' or the 'Company') Statement re Share Price Movement The board of ValiRx notes the recent increase in the Company's share price and confirms that it is not aware of any reason that would lead to such a movement. And before that I cannot find a similar statement...of course I could be wrong.. Lol Oh no the trolls are back in force we are doomed.. 👎👎👎👎 8078;👎Ԁ78;
09/3/2018
13:59
thebossman: MaxHSpringer Posts: 5,829 Off Topic Opinion: No Opinion Price: 3.00 View Thread (8) Email to Tarquin Today 13:14 Dear Mr. Edwards, I write to you with a handful of queries and concerns that I share with other private investors in VAL. I have invested in VAL because I believe that the science behind VAL 201, 301 & 401 is very good and has the ability to potentially revolutionize the treatment of various Cancers in patients. I am sure that you will agree that this is a very exciting time for VAL and the goal is now on the horizon. My concern and query is the fact that as much as we are in an exciting period of VAL's life cycle, I along with other investors feel that there is a distinct lack of communication and a disconnect of VAL's BOD from its private investors and the wider market. The optics of this and perceived business decisions that would leave room for improvement have had a less than positive effect on investor confidence and willingness to invest more into VAL at this point in order to allow the share price to reflect, what should be VAL's true value at this point. As you would agree, the companies that have a consistent flow of communication with its private investors and wider market are the ones that attract the most attention and investment. An example of VAL's missed opportunities is the recent publication of the US Patent Office letter confirming that the patent should be awarded by the 20th of March 2018. This is a letter that VAL would have received, is price sensitive and just as important- is a very important milestone that all invested would love to know. Price sensitive and information of interest are not just those that are negative or extremely positive, but those that are also somewhere in the middle (little victories). I realize that many BOD's feel that communicating with its private investors is a pain and can not be bothered, but those are the companies that hold their investors in contempt and the market tends to punish these companies in my opinion and I tend to avoid these. So, Mr. Edwards, I along with many others would like to request of you and the BOD that more effort be made to communicate on a more regular basis with the private investors and wider market on during these seemingly small milestones on our journey. We would like to not only share in the monetary success of the business but also on its triumphs that allow us to all share in this journey! Please feel free to contact me in order to share ideas that the business will put forward, including communications, public relations, more interviews and VAL's participation in industry events. ......................................................................... .......................................................................... Do really think he is going to read all of that email..Why not just say when are our BODs going to get their fingers out or words to that effect..Short and Sweet!
03/1/2018
20:00
margic: Good news tomorrow would be good timing from the bod. Something for the market to get stuck into. Personally I think Val 201 results would be a good catalyst and a great start. Pharma deal would be great but I suspect they will get other news filters and updates through before announcing anything should a deal go ahead. That it certainly has potential to be truly transformational for the company so would no doubt require a quick re-rate. With the share price higher of the back of Val 201 results, Val share price will be very well placed to see a huge increase on the years highs. Today, unfortunately was very predictable. Probably much the same tomorrow I would have thought. It will need a significant buying frenzy or good news to change direction this week. The gap will still be filled at some point without a shadow of a doubt. That's simply because it always does!
03/1/2018
17:27
thebossman: ValiRx Clinical efficacy of VAL401 ValiRx is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company’s two leading assets are in clinical trials: VAL201 (Phase I/II) – a peptide for advanced prostate cancer and potentially other hormone- induced indications; and VAL401 (Phase II) – a reformulation of risperidone, in trials for lung cancer. Early clinical analysis of its Phase II trial with VAL401 has been released, meeting its primary endpoint by providing a statistically significant improvement in the overall survival rate. Further data will be revealed in due course. ► Strategy: ValiRx operates as a virtual business, out-sourcing most of its activities. The core strategy is to develop its therapeutic assets through the clinical pathway and seek a partner/licensing deal to complete the development programme and regulatory submissions to commercialise the products. ► Overall survival data: The newly published data on non-small cell lung cancer patients that exhausted all possible existing therapies, provide statistically significant improvement in the overall survival rate. Further analyses in quality of life and characterising the best responders will be revealed in due course. ► Valuation: This data provides an important value inflection point which was not reflected previously in the share price. The market has reacted promptly to this news, with the share price jumping from 1p at the end of November (capital increase) to 7.73p – a near eight-fold increase! ► Next steps: Safety and tolerability of VAL401 has been confirmed in late stage patients affected by non-small cell lung cancer. The study has provided also the dosing level that will be used in subsequent trials. Full data analysis is underway, and the final read-out of the study is expected in the near future. ► Investment summary: The market has failed to recognise the potential of ValiRx, fretting more about the need for more capital to advance its clinical programmes that taking a rational view of the likely success of its clinical candidates. Given the clinical progress seen to date, the company will be attracting the attention of potential commercial partners and/or institutional investors in order to achieve the true value of its assets.
18/12/2017
22:36
margic: Nobby, thanks thats insightful and would seem an appropriate approach when you consider the levels of companies involved and that there is a procedure in place in how tenders and offers are received and/or issued/ordered. Val have confirmed discussions from what I could see. It's always nice to hope that the reason the gap held is because there's another one coming tomorrow. That's a couple of major news items in recent days and these things tend to or used to come in 3-4's . Interesting to see how Val share price now plays out. If it does go much below 7p to buy then it's advisable to wait it out for 5.5p or better if you can depending how you look at it and what your strategy here is. Mine will be different to others and different others will differ to the rest. ;)
07/12/2017
19:14
h2owater: ValiRx shares yo-yo on fundraising and pipeline update by Phil Taylor | Dec 1, 2017 9:07am Chairman Oliver de Giorgio-Miller says ValiRx has made big progress in the last 6 months. ValiRx is approaching a pivotal point in its development as it waits for clinical results from two lead programs that it hopes will net it a development partner. The U.K.-based biotech—which has just raised £1 million (around $1.3 million) in a fundraising round—expects to disclose phase 1/2 data on lead drug VAL201 in prostate cancer later this month, along with midstage data for lung cancer candidate VAL401. News of the fundraising and clinical update sparked a short-lived spike in ValiRx shares on the London AIM, although it was quickly reversed, doing little to counteract what has been a fairly steady decline in the stock over the past year. The new funds will be used for “advancing the clinical trial of VAL201 and for the preclinical progress of other programmes,” said the company in a statement, adding that it believes the share price rise is “a consequence of comments and analysis surrounding the company's developmental pipeline.” VAL201 is a peptide drug, delivered by subcutaneous injection, that is being tested in a single-agent trial in patients with locally advanced or metastatic advanced prostate carcinoma. In September, the company said it had seen signs of clinical activity, including a reduction in the prostate cancer biomarker PSA and disease stabilization, with no serious safety issues in patients treated to that date. Meanwhile, VAL401—being taken forward by ValiRx’ ValiSeek unit—is a repurposed drug, a new formulation of risperidone that has more than two decades of clinical experience as an antipsychotic treatment, and ValiRx hopes to show in the forthcoming trial that it can improve quality of life in patients with advanced lung cancer. Pharmacokinetic data reported in September showed that VAL401 behaved like current formulations of risperidone, which should allow ValiRx to reference earlier trials as prepares for additional studies and—potentially—future marketing applications. It also suggested a dose for future trials of 2mg, which is well within the usual dosing range for risperidone. ValiRx’ nonexecutive chairman Oliver de Giorgio-Miller said at the time that the company has “seen considerable progress across our therapeutic portfolio in the last six months, adding value to the company's assets and bringing us closer to the point where our clinical programmes for VAL201 and VAL401 will deliver meaningful data and will bring the company closer to finding a partner.” hTTp://www.valirx.com/events/valirx-plc-targeted-anti-cancer-therapies-val201/
Valirx share price data is direct from the London Stock Exchange
add chat code
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20180715 19:47:16